ReviewCurrent diabetes reports2010
The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease.
Review in Current diabetes reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Renal biomarkers for assessment of kidney function in renal transplant recipients: how do they compare?International urology and nephrology · 2012Trial
- Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directions.Kidney research and clinical practice · 2026Article
- Article
- Increased level of TXNIP and nuclear translocation of TXN is associated with end stage renal disease and development of multiplex renal tumours.BMC nephrology · 2024Article
- Association between engulfment and cell motility 1-gene polymorphisms and diabetic nephropathy in an Egyptian population with type 2 diabetes.Journal of diabetes and metabolic disorders · 2022Article
- Melatonin and/or rowatinex attenuate streptozotocin-induced diabetic renal injury in rats.Journal of biomedical research · 2019Article
- The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.Cardiovascular diabetology · 2019Article
- Subclinical First Trimester Renal Abnormalities Are Associated With Preeclampsia in Normoalbuminuric Women With Type 1 Diabetes.Diabetes care · 2018Article
- Identification of potential biomarkers and therapeutic targets for human IgA nephropathy and hypertensive nephropathy by bioinformatics analysis.Molecular medicine reports · 2017Article
- The variation of macro- and micro-minerals of tissues in diabetic and non-diabetic rats.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2017Article
- Combination of melatonin and certain drugs for treatment of diabetic nephropathy in streptozotocin-induced diabetes in rats.Diabetology international · 2016Article
- Article
- Kidney injury molecule-1 as a predicting factor for inflamed kidney, diabetic and diabetic nephropathy Egyptian patients.Journal of diabetes and metabolic disorders · 2015Article
- Renal recovery.Critical care (London, England) · 2014Article
- Article
- Measurement of renal function in patients with chronic kidney disease.British journal of clinical pharmacology · 2013Review
- A pilot metabolic profiling study in serum of patients with chronic kidney disease based on (1) H-NMR-spectroscopy.Clinical and translational science · 2012Article
- The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer.Biochimica et biophysica acta · 2012Review
- Increased Urine IgM and IgG(2) Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes.Biochemistry research international · 2012Article
- Acute kidney injury in childhood: should we be worried about progression to CKD?Pediatric nephrology (Berlin, Germany) · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently used measures to assess kidney function and injury are largely inadequate. Markers such as serum creatinine, formulas to estimate glomerular filtration rate, cystatin C, and proteinuria largely identify an underlying disease process that is well established. Thus, there has been a recent effort to identify new biomarkers that reflect kidney function, early injury, and/or repair that ultimately can relate to progression or regression of damage. Several biomarkers emerged recently that are able to detect kidney damage earlier than is currently possible with traditional biomarkers such as serum creatinine and proteinuria. Identification of urine biomarkers has proven to be beneficial in recent years because of ease of handling, stability, and the ability to standardize the various markers to creatinine or other peptides generally already present in the urine. Recent markers such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and podocin have garnered a lot of attention. The emergence of these and other biomarkers is largely because of the evolution of novel genomic and proteomic applications in investigations of acute kidney injury and chronic kidney disease. In this article, we focus on the applications of these biomarkers in disease.
Indexed as
Identifiers
20425065What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.